Researcher
Marc Ferrante
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Feb 2004 → Today
Projects
1 - 10 of 16
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Model informed Dosage optimization of Crizanlizumab for the management of Sickle Cell Disease in TanzaniaFrom17 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding and treating symptom burden in inflammatory bowel diseases: a psychological perspectiveFrom1 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The gut barrier as master regulator of microbiome-host interactions: exploring the structure and function of paracellular and transcellular transport in the large intestine.From1 Oct 2021 → TodayFunding: BOF - various, BOF - projects
- From drug development to registration: optimalization of flow processesFrom10 Feb 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Advanced 3D Complex Tissues BioAssembly Platform for Precision Disease Modeling, Drug Discovery and Regenerative Medicine (3D-BioBOT)From1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- H2O Health Outcomes ObservatoryFrom1 Oct 2020 → TodayFunding: H2020 - Health, demographic change and wellbeing
- OrganID: Organ-derived complex 2D/3D cultures in human diseaseFrom1 Oct 2020 → TodayFunding: FWO Strategic Basic Research (SBO)
- LONG-TERM SEQUENTIAL USE OF BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE: HARMLESS OR HAZARDOUS?From1 Aug 2017 → 24 Sep 2021Funding: FWO fellowships
- Predicting response to treatment in patients with inflammatory bowel diseaseFrom1 Jan 2017 → 31 Dec 2022Funding: Foreign private sponsor - undefined
Publications
381 - 390 of 468
- Systematic Versus Endoscopy-Driven Treatment With Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence: Interim Results From a Randomized, Multicenter Trial(2014)
Authors: Marc Ferrante, Konstantinos Papamichael, Dana Duricova, Geert R D'Haens, Séverine Vermeire, Emmanuel J Archavlis, Paul Rutgeerts, Martin Bortlik, Gerassimos J Mantzaris, Gert Van Assche
Pages: S592 - S592 - Predominant Gut Microbiota Predict Pouchitis Following Colectomy and IPAA in Ulcerative Colitis(2014)
Authors: Kathleen Machiels, Marie Joossens, Ingrid Arijs, Isabelle Terrasson, Vera Ballet, Marc Ferrante, Jan Verhaegen, Kristel Van Steen, Anthony de Buck van Overstraeten, Albert Wolthuis, et al.
Pages: S832 - S833 - ER Stress and Autophagy-Related Susceptibility Loci Translate Into a Measurable Functional Response in Crohn's Patients: A Potential Tool for Personalized Medicine(2014)
Authors: Kris Nys, Wiebe Vanhove, Isabelle Cleynen, Marc Ferrante, Gert Van Assche, Paul Rutgeerts, Patrizia Agostinis, Séverine Vermeire
Pages: S35 - S35 - Efficacy and Safety of Anti-TNF Therapy in Elderly Patients With Inflammatory Bowel Disease(2014)
Authors: Triana Lobaton Ortega, Séverine Vermeire, Vera Ballet, Paul Rutgeerts, Gert Van Assche, Marc Ferrante
Pages: S579 - S579 - Strong Mucosal Upregulation of AIM2 and IFI16 Inflammasomes in Patients With Active Inflammatory Bowel Disease(2014)
Authors: Wiebe Vanhove, Dominiek Staelens, Paul Peeters, Jan Van der Goten, Seppe De Schepper, Isabelle Cleynen, Emiel F Wouters, Gert Van Assche, Marc Ferrante, Séverine Vermeire, et al.
Pages: S643 - S643 - PRIMARY RESPONSE TO INFLIXIMAB THERAPY IN IBD PATIENTS IS REFLECTED IN THE NORMALISATION OF THE HAEMOSTATIC PROFILE(2014)
Authors: Lize Bollen, Niels Vande Casteele, M Peeters, Paul Declerck, Marc Ferrante, Séverine Vermeire, Ann Gils
Pages: S6 - S7 - Biomarker Panel for Prediction of Mucosal Healing in Patients With Crohn's Disease Under Infliximab Therapy(2014)
Authors: Magali de Bruyn, Talat Bessissow, Thomas Billiet, Isabelle Cleynen, Richard Kirkland, Xinjun Liu, Scott Hauenstein, Katherine Drake, Sharat Singh, Marc Ferrante, et al.
Pages: S428 - S428 - Differential Expression of MicroRNAs in Ileal Mucosa of Patients With Early, Recurrent and Late Crohn's Disease(2014)
Authors: Jan Van der Goten, Ingrid Arijs, Leentje Van Lommel, Sophie Organe, Wiebe Vanhove, Gert Van Assche, Marc Ferrante, Paul Rutgeerts, Frans Schuit, Séverine Vermeire
Pages: S875 - S876 - Prediction of Primary Response to Infliximab in Crohn's Disease: A Matrix-Based Prediction Model(2014)
Authors: Thomas Billiet, Magali de Bruyn, Vera Ballet, Karolien Claes, Xinjun Liu, Richard Kirkland, Katherine Drake, Steven Lockton, Fred Princen, Sharat Singh, et al.
Pages: S239 - S239 - Prevention of Recurrent Clostridium difficile Infection by Neutralizing Monoclonal Antibodies in a Hamster Relapse Model(2014)
Authors: Dominiek Staelens, Marlies Van de Wouwer, Els Brouwers, Silvia Caluwaerts, Pieter Rottiers, Peter Vanhoenacker, Nick Geukens, Paul Declerck, Marc Ferrante, Séverine Vermeire, et al.
Pages: S250 - S250
Patents
1 - 5 of 5
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)